Go FDAkeepsmovingthehurdles.com and you'll find your answer.

You attack the CEO....why not attack you? Both are fair game.

Like I said before, some dont have a clue what Doc has done for Vivos. And it's a crying shame. Vivos didn't start from ground Zero. It started 50 floors below ground Zero with financial death starring Doc in the face when he was elected as CEO. Now, 7 years later we are debt free and on the cusp of an IDE approved medical device that with save millions of pets and humans lives.

Doc's feats and accomplishments are real and factual. And if one took a better look.....they will see how a old man's work will make a poor man rich.

No penny stock CEO other then Dr. Mike Korenko has pulled a company from financial death to possibly becoming a cancer killing conglomerate company. Fact!!



https://www.radiogel.com/

Aww, you found a friend and now used the word "we". As in you and globoy. How cute.

You're another that hasn't a clue who Korenko is.





https://www.radiogel.com/

Nope, Korenko is here to stay. So get it out of your head.

Someday you'll find out why Korenko was picked as CEO and will want to shake his hand. As of right now....you haven't a clue who he is.




https://www.radiogel.com/

From Mike Korenko, Sc. D. • CEO • President of Vivos Inc.

“We are excited about expanding the availability and awareness of the Isopet® Precision Radionuclide Therapy as a game changing treatment option for treating solid tumors. Pet parents need a reasonable driving distance to obtain the therapy and we are working diligently to continue to expand our reach domestically and in certain international markets. We now have seven Isopet® certified regional clinics located in Washington, Missouri, Maryland, New York, New Hampshire, and Indiana and are in active discussions related to new Isopet® clinic certifications in Wisconsin, Texas, California, and Washington.”

Vivos Inc, Isopet, and Radiogel

Vivos Inc is a biotechnology company that specializes in the development of radiotherapeutics for the treatment of cancer. The company has gained attention for its innovative products, Isopet and Radiogel, which have shown promise in the field of cancer treatment.

Isopet

Isopet is a groundbreaking therapy developed by Vivos Inc. It involves the use of a proprietary radioisotope to target and destroy cancer cells while minimizing damage to healthy tissues. This targeted approach has the potential to revolutionize cancer treatment by offering a more effective and less invasive alternative to traditional therapies.

The technology behind Isopet allows for precise localization of radiation, which can lead to improved treatment outcomes and reduced side effects for patients. This therapy has shown promising results in preclinical studies and is currently being evaluated in clinical trials for various types of cancer.

Radiogel

Radiogel is another innovative product developed by Vivos Inc. It is designed to deliver localized radiation therapy directly to solid tumors. The gel-based formulation allows for the precise placement of radiation, offering a targeted approach to treating cancer while minimizing exposure to healthy tissues.

This approach has the potential to enhance the effectiveness of radiation therapy while reducing the risk of complications commonly associated with traditional radiation treatments. Radiogel has demonstrated promising results in preclinical studies and is also undergoing clinical evaluation for its efficacy in treating different types of solid tumors.

Both Isopet and Radiogel represent significant advancements in the field of cancer treatment, offering new hope for patients facing various forms of cancer. The targeted nature of these therapies holds promise for improving treatment outcomes and quality of life for individuals battling this devastating disease.

In conclusion, Vivos Inc’s Isopet and Radiogel are cutting-edge therapies that have the potential to transform the landscape of cancer treatment. Their targeted approach to delivering radiation therapy offers new possibilities for more effective and less invasive treatments, bringing hope to patients and healthcare providers alike.

Vivos Inc Radiogel

Vivos Inc is a company that has developed a product called Radiogel, which is used in the treatment of cancer. Radiogel is a brachytherapy device that delivers therapeutic radiation directly to the tumor site. It is designed to be minimally invasive and can be used to treat various types of solid tumors, including breast, prostate, and lung cancers.

Radiogel works by injecting tiny radiation-emitting beads directly into the tumor. These beads deliver a high dose of radiation to the cancerous cells while minimizing exposure to surrounding healthy tissue. This targeted approach helps to reduce side effects and improve treatment outcomes.

One of the key advantages of Radiogel is its ability to be administered on an outpatient basis, allowing patients to undergo treatment without the need for a hospital stay. This can lead to improved quality of life for patients undergoing cancer treatment.

The development of Radiogel represents a significant advancement in the field of cancer therapy, offering a promising option for patients with solid tumors. Clinical trials and studies have shown promising results, and the use of Radiogel continues to be explored in various cancer treatment protocols.

In summary, Vivos Inc’s Radiogel is a brachytherapy device that delivers targeted radiation therapy for solid tumors, offering potential benefits such as reduced side effects and improved quality of life for patients

Vivos Inc. Radiogel Genotoxicity Testing

In 2023, Vivos Inc., a pharmaceutical company specializing in cancer treatment, completed genotoxicity testing for its product Radiogel. Genotoxicity testing is a crucial step in the development of new pharmaceuticals to assess the potential genetic damage caused by the product. This testing helps ensure the safety and efficacy of the medication before it is approved for use in patients.

Radiogel is a brachytherapy device developed by Vivos Inc. for the treatment of solid tumors. It delivers targeted radiation therapy directly to the tumor site, minimizing damage to surrounding healthy tissue. As part of the regulatory approval process, genotoxicity testing is conducted to evaluate whether Radiogel has the potential to cause mutations or other genetic damage.

The completion of genotoxicity testing in 2023 indicates that Vivos Inc. has fulfilled this important regulatory requirement for Radiogel. This milestone brings the company closer to potentially obtaining approval for the use of Radiogel in clinical settings, offering new hope for cancer patients in need of advanced treatment options

Mayo Clinic Protocol and Institutional Review Board (IRB)
After receiving FDA approval to conduct clinical trials we need formal approval from the Mayo Clinic IRB. In anticipation of this step and to help expedite the proccess we have submitted the Clinical Trial Protocol to their “gatekeeper” for comments. We have also been conducting certification training for Dr. Paz Fumagalli. Next quarter we are planning to complete the final training certification step using high activity RadioGel™ in a full-dress rehearsal operating theater.

Animal Therapy Marketing
Marketing to pet parents, clinic owners, veterinarians, and oncologists is complex. Aside from utilizing advertisements in key journals and the social media, the following activities are important:



1. Open new small animal and equine clinics that are reasonably close for pet parents to access.



a. This quarter we certified a new small animal clinic, Indian Creek Veterinary Hospital in Fort Wayne IN, and two new equine clinics, Myhre Equine Clinic in Rochester NH and Hopkinton Animal Hospital in Weare NH.



b. We are currently in contact with several other clinics.



2. Participate in conferences to interface with the animal therapy community.



a. Last Quarter

VSPA Spring Conference in Saint Paul MN
American College of Veterinary Internal Medicine, ACVIM in Philadelphia PA
b. This Quarter

11th International Conference on Isotopes in Saskatoon Canada
Nigel Stevenson from Exubrion Therapeutics® and I presented a joint paper entitled “Precision Radionuclide Therapy for Treating Veterinary Cancerous Tumors and Osteoarthritis.”
Washington State Veterinary Medical Association, WSVMA in Tacoma WA
c. Next Quarter

Veterinary Cancer Society, VCS in Reno NV
American Association of Equine Practitioners, AAEP in San Diego CA
d. Next Year

American College of Veterinary Internal Medicine, ACVIM in Minneapolis MN
American Association of Equine Practitioners, AAEP in Orlando FL.
International Radiation Protection Association (IRPA) and IRPA 16th International Congress and 69th Health Physics Society Annual Meeting in Orlando FL
Dr. Darrell Fisher submitted an abstract: “Direct Interstitial Injection: An Approach to Optimizing Therapeutic Ratios for Safe and Effective Delivery of High-dose Radionuclide Therapy in Treating Solid Tumors”
– Darrell R. Fisher, Versant Medical Physics and Radiation Safety; Michael K. Korenko, Vivos, Inc.



3. Perform animal studies that result in publications in key journals.



a. Next quarter we will complete the VX2 tumor injection at Johns Hopkins Veterinary Clinical Trial Network within the approved IUCUC protocol. This will result in two publications.


b. Next year we intend to follow-up with a new small animal study at JHU and an equine study at a university located near “equine territory.”


c. Longer term we will conduct other studies using mice models to support future indications for use, such as lung cancer.



4. Next quarter Dr. Bill Bradly, owner of the New England Equine Practice, will conduct an experiment to determine if IsoPet is effective in treating caudal heel pain syndrome, sometimes called navicular syndrome. This is a complex syndrome, but if IsoPet is effective, this is a new and large market.

Injection System Production
We finalized and patented our support equipment from shipping to therapy. We are currently focusing on developing an inventory of each item.

Quality Management System
We have created a robust Quality Management System. This includes documents, GLP validations, and GLP test plans and reports. This is necessary to prepare for FDA audits that occur when we initiate human clinic studies

IDE will be successfully submitted in the next 3 months. Facts are facts.




https://www.radiogel.com/

Find me another CEO in OTC with his credentials?

Boy, I dont know. Reading Doc credentials, it doesn't appear to me he's not a liar. He has quite an accomplished life history actually. And I'd bet any amount of money he's the best CEO in the OTC, and on the big boards.


Michael K. Korenko, Sc.D.
President • CEO Vivos, Inc.


Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.

He currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.

Dr. Korenko served as Vice-President of Westinghouse Hanford, Executive Vice President of Closure at Rocky Flats and Chief Operating Officer for Curtiss-Wright Electro-Mechanical Division producer of the nuclear components for all the United States submarines and aircraft carriers and for commercial nuclear power reactors.

He is currently CEO and President of Vivos Inc. developing yttrium-90 brachytherapy for animals and humans.

Yeah, your right. Doc must of had a whole backyard full of tumored rabbits he need to get rid of. What was I thinking?

Bedside, Doc loves jabbing rabbit on his spare time. Gives him something to do when he's not at horse shows.

Oh, and by the way.....throw in a Genotoxicity test when your done with the bugs bunnies testing.

Oh yes, you mean the 9 rabbits FDA first requested, then FDA requested another 9, then requested 18 more, and so on....

And CEO reports quarterly to say "after the 9 rabbits testing we can submit IDE".

I can see how that would make a liar out of CEO if FDA keeps moving the rabbit hurdles. Sucks!

Where do you think the Doc gets his data from to feed the IDE submission.

Hint: sometimes you walk it on a leash, and some our kept in a barn. YW


And btw....higher highs and higher lows today.

Did you see the one pound tumor they killed on a horse? If not, Im sure they have a optometrist in your area.

Is that what you get paid per post? 2 cents? Sunlight gets .03 and sc8 gets 5 cents. Opps! Maybe you wasn't supposed to know. Sorry!

Yeah, I'm sure investors who are buying VVOS think their actually buying RDGL After all.....symbols appear to be the same. And thier devices are very close in comparison.

Holy crap....where do they find these people?.

Hi Debbie Downer!!

Radiogel.....coming to a human tumor near you.

Isopet.....already coming to pet tumor near you.

But yet you're still an investor. Wow!

Great post! The poster in question is so transparent you figured him out in one post. Awesome!





https://www.radiogel.com/

Here's a lists of attendees in alphabetical order. They dont give their booth number.

https://convention.aaep.org/meet-our-exhibitors

Yup, these clown monkey's days are numbered.

You never called for bankruptcy, but insinuated the word many times in your posts. Seems strange to be a cheerleader for the death of a stock you say you own.

Yup, pissed off Friday for that little one.

When your crap....treat them as such. Why aren't you cheerleading the share price today? Never mind.....i know why.

Genotoxicity testing will pass with flying colors. The added 28 rabbit studies will do the same. Its the FDAs unforseen additional testing is what will take for ever.

You avoided my question. Answer it.

Otherwise your a fake.

What does FDA clearly need?

How is focusing on Isopet detrimental to Radiogel?

You do know that is where 100% of Radiogel's data comes from right?

Without animals there is no Radiogel. Period!

So, because Mayo Clinic has not made a public statement in regards to their involvement with Vivos inc and Radiogel, you say there isn't any? Wow Wow Wow!

Sure glad i dont base my investments on your options. I'd be broke by now.